/
PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for surgical and post-operative pain management. Its core product, PRF-110, is designed as an oil-based, viscous solution applied directly into the surgical wound bed before closure to provide localized and extended analgesia. The company’s work centers on improving drug delivery in areas where sustained pain control and targeted treatment are important, particularly in hospital-based surgical settings. PainReform Ltd. operates in the healthcare and drug development sectors, where it contributes to the development of specialized treatment options built around existing active ingredients and delivery technologies. Headquartered in Israel, the company remains focused on advancing products intended for post-operative care and other clinical applications.
$1.19
+$0.01 (+0.85%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-30129.41% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$4M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$17K
Net Income (TTM)
-$5M
▲ +65.6% YoY
Op. Margin
-30129.41%
ROIC
-72.39%
▲ +179.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$4M
▲ +68.7% YoY
Op. Cash Flow (TTM)
-$4M
▲ +68.7% YoY
Net Debt
-$4M
Net Cash Position
Cash & Equiv.
$4M
Continue Research
PainReform (PRFX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, PainReform scores 18/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
PainReform scores 18 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -30,129.4% operating margin and a -72.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh PRFX's valuation and scores 18/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.